C4B and neoplasm: We investigated CHIP and TI-CH in 31,556 patients with matched blood and primary tumor samples across 75 cancer types (Table S4 and Fig S18–S19).23,24 CHIP was observed in 24% (7,450/31,556) of patients with a 5.3% median blood VAF (IQR 3.1-11.9).